Exploring vimentin's role in breast cancer via PICK1 alternative polyadenylation and the miR-615-3p-PICK1 interaction.

Breast cancer continues to be a major health issue for women worldwide, with vimentin (VIM) identified as a crucial factor in its progression due to its role in cell migration and the epithelial-to-mesenchymal transition (EMT). This study focuses on elucidating VIM's regulatory mechanisms on the miR-615-3p/PICK1 axis. Utilizing the 4T1 breast cancer cell model, we first used RNA-seq and proteomics to investigate the changes in the APA of PICK1 following VIM knockout (KO).

Saffron improves the efficacy of immunotherapy for colorectal cancer through the IL-17 signaling pathway.

Ethnopharmacological Relevance: Saffron is one of the traditional medicinal herbs, which contains various active ingredients, such as safranal, crocin, saffron acid, etc. It has anti-inflammatory, antioxidant, and anti-cancer properties, and is widely used in clinical practice. The anti-cancer efficacy of saffron has been previously confirmed, but its anti-cancer mechanism in colorectal cancer remains unclear.

A case report of thalidomide in the treatment of camrelizumab-induced reactive cutaneous capillary hyperplasia.

Rationale: Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most prevalent immune-related adverse event observed in patients undergoing camrelizumab treatment, and there is a lack of effective therapeutic strategies. Thalidomide (THD) has anti-inflammatory, immunomodulatory, antiangiogenic, and antitumor properties, which have led to its use in various autoimmune diseases, hematological malignancies, solid tumors, and other disorders.

Patient Concerns: A 52-year-old male patient with lung cancer developed vascular moles on his face, neck, and back after 3 cycles of chemotherapy comprising pemetrexed and carboplatin combined with camrelizumab immunotherapy.

The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report.

Background: Primary nuclear protein in testis (NUT) carcinoma is a rare malignant tumor originating from the salivary glands that usually occurs in midline structures, such as the head and neck, and has been identified in young patients. Progression of NUT carcinoma is rapid, and there is a high degree of malignant invasion. The median survival time of NUT carcinoma patients is 6 to 9 months, and 80% of the patients die within 1 year after diagnosis.

Sintilimab treatment for ureteral carcinoma following bladder cancer leads to leukopenia: a case report.

Herein, we present a case report of sintilimab treatment for a patient with ureteral cancer reoccurring after bladder cancer, and exploration of the mechanism of adverse reactions from the aspects of intestinal flora and immunity. We have reported a case of leukopenia in a patient with recurrent ureteral cancer after bladder cancer who was treated with sintilimab. A 52-year-old Chinese man with a history of hypertension and diabetes presented with lower urinary tract symptoms, including painless hematuria, frequent and urgent urination, and micturition without pain.